- Mankind Pharma Limited (NSE: MANKIND, BSE: 543904) approved the purchase of 70 % of Armed Cell Therapeutics B.V. (ACTx), paying EUR 48 million in cash (instalments) to secure a foothold in next‑generation CAR‑T cancer therapies.
- The Board also authorized an additional EUR 45 million investment in its Dutch subsidiary, raising the total authorized capital to EUR 50 million (including the earlier EUR 5 million approval).
- The extra capital will fund the EUR 48 million cash consideration for the ACTx stake and support Mankind’s long‑term, innovation‑led strategy.
- The acquisition gives Mankind entry into CAR‑T programs targeting non‑Hodgkin lymphoma and small‑cell lung cancer, aligning with its goal to build a global, research‑focused pipeline.
- The deals are subject to required regulatory approvals in Belgium/Netherlands; no specific completion date was disclosed.
The acquisition of a 70% stake in Armed Cell Therapeutics B. V. (ACTx) for EUR 48 million (~₹440 Crore) in cash instalments expands Mankind Pharma's specialty R&D pipeline into high-barrier CAR-T oncology therapies.
Sign in for impact outlook, horizons, comparables, and full intelligence analysis.
Forecast from comparable, historic events. Not investment advice.
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka